Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Colorectal Neoplasms 234Carcinoma, Non-Small-Cell Lung 132Breast Neoplasms 121Glioblastoma 88Ovarian Neoplasms 86Carcinoma, Hepatocellular 69Rectal Neoplasms 64Brain Neoplasms 58Lung Neoplasms 55Neoplasm Metastasis 54Neoplasms 52Colonic Neoplasms 50Fallopian Tube Neoplasms 43Glioma 40Carcinoma, Renal Cell 35Gliosarcoma 34Melanoma 26Adenocarcinoma of Lung 26Pancreatic Neoplasms 23Liver Neoplasms 23Uterine Cervical Neoplasms 21Stomach Neoplasms 21Recurrence 21Triple Negative Breast Neoplasms 18Kidney Neoplasms 16Endometrial Neoplasms 16Esophageal Neoplasms 15Astrocytoma 14Carcinoma, Ovarian Epithelial 13Adenocarcinoma, Bronchiolo-Alveolar 13

Interventions

Paclitaxel 2etoposide phosphate 1Taxes 1Platinum 1Nivolumab 1Immunoglobulin G 1Disulfides 1Cisplatin 1Carboplatin 1Bleomycin 1Bevacizumab 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Sertoli-Leydig Cell Tumor × Bevacizumab × Clear all
NCT00748657 2019-07-23

Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary

National Cancer Institute (NCI)

Phase 2 Completed
36 enrolled 7 charts
Gynecologic

Granulosa cell tumor of the ovary, Ovarian gynandroblastoma, Sertoli-Leydig Cell Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡